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Objectives: To assess the yearly frequency of ranibizumab injections for the treat-
ment of wet Age-Related Macular Degeneration (wAMD) in two large Canadian 
public drug plans: Ontario Public Drug Program (OPDP) and Régie de l’assurance-
maladie du Québec (RAMQ). MethOds: Pharmastat database (IMS Health Canada 
Inc.) was used to assess the mean annual number of ranibizumab injections for 
wAMD patients covered by the OPDP or RAMQ drug plans (1 injection was defined 
as 1 claim). Only wAMD treatment-naïve patients were included and the index 
date was defined as the date of the first ranibizumab claim. The analysis looked 
at monthly data from March 2008 to November 2012 for OPDP patients and from 
January 2008 to May 2012 for RAMQ patients and tracked the mean number of 
claims during the patient’s first, second, third and fourth year of ranibizumab 
therapy. Results: For the OPDP, the mean number of ranibizumab injections was 
6.0, 5.4, 5.5 and 5.6 for year 1 (N= 26,606), year 2 (N= 19,466), year 3 (N= 12,708), and 
year 4 (N= 6,681), respectively. For the RAMQ, the mean number of injections was 
5.4, 4.7, 5.2 and 5.7 for year 1 (N= 3,457), year 2 (N= 2,185), year 3 (N= 1,178), and year 
4 (N= 349), respectively. cOnclusiOns: These results suggest that many Ontario 
and Quebec retina specialists and ophthalmologists do not treat monthly but rather 
adopt an individualized ranibizumab treatment regimen to manage their patients’ 
wAMD. In addition, these results provide information on the real-world utilization of 
ranibizumab in wAMD for up to four years of treatment. The analyses, conclusions, 
opinions and statements expressed are those of Novartis Pharmaceuticals Canada 
Inc., and not those of IMS Health Canada Inc.
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Objectives: To date, there has not been extensive study on the economics or estab-
lished treatment guidelines in patients with non-infectious posterior uveitis (NIPU). 
Current treatment is mostly topical/systemic/injection corticosteroids, though treat-
ment is associated with significant side effects. We undertook a secondary research 
analysis of MarketScan claims data to better understand the patient journey and the 
current treatment standard of care for NIPU patients. MethOds: We analyzed the 
MarketScan dataset to identify NIPU patients from a defined list of ICD-9 codes. We 
then identified patients with 30 months of continuous enrollment data, 6 months 
prior and 24 months post initial diagnosis. Patients were assessed for number of 
office visits/procedures, number of diagnostic tests, number of inpatient stays, and 
number and frequency of drug treatment (corticosteroids, corticosteroid injections, 
immunomodulators, and biologics). Results: Of the 56 million lives in the claims 
dataset, 34,827 had an ICD-9 code consistent with NIPU. Of these unique patients, 
33,386 were analyzed. 78.8% of patients came from the commercial dataset, 59% 
of patients were female, and the average age at diagnosis was 51.5 years. Prior to 
diagnosis, 5,775 patients were treated for NIPU at an average cost of $185.43 per 
patient (58.0% topical/systemic corticosteroids, 22.7% corticosteroid injections, 
15.7% immunomodulators, 3.7% biologics). In the 24 months post-diagnosis, the 
number of treated patients increased to 11,570 patients at an average cost of $249.01 
per patient (45.7% topical/systemic corticosteroids, 37.4% corticosteroid injections, 
16.4% immunomodulators, 3.2% biologics). Examining each six-month period post-
diagnosis, the number of treated patients decreased, but the share of treatments 
remained the same. cOnclusiOns: Patients with NIPU are engaging the health 
care system and being treated for NIPU at least six months prior to an official 
diagnosis. Efforts should be made to better identify patients with NIPU to ensure 
proper diagnosis and treatment.
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Objectives: Waiting time for medical consultation is an important quality indi-
cator of health systems. International studies have shown that there is consider-
able variation of waiting time between countries. It may also vary within countries 
depending on the degree of emergency, indication, and way of reimbursement. Our 
objective was to assess practice organization and waiting times in German derma-
tological practices. MethOds: A one page questionnaire was sent to be returned 
anonymously by fax to 2,644 German office base dermatologists randomly selected. 
Included were items on organization of practice, region and specific average waiting 
times for selected diagnoses. The postal codes obtained from the practices were 
mapped to the 17 German regions of physicians association of statutory health 
insurance. Results: Data sets were obtained from 681 practices. A total of 4.3% of 
practices rarely or never gave fixed appointments, 36.3% only gave fixed appoint-
ments. The percentage of treatment at fixed appointments varied by regions from 
71.1% in Bremen and Brandenburg to 90.0% in Hessen. Moreover, private practices 
not being associated with the statutory health system showed a higher rate of timed 
appointments with 94.8% compared to 83.0%. Average waiting time in practices 
treating also patients with statutory health insurance is 5 weeks and thus 4 times 
higher compared to waiting time in practices treating private insured patients only 
(1.2 weeks). There was large variation in waiting time for the first appointment 
between different indications. Patients with acute eczema or pigmented lesions 
specific for melanoma were given appointments after 1.7 or 1.2 weeks, respec-
tively; for skin cancer screening, patients had to wait for 5.7 weeks on average. 
There was only small geographic variation regarding this pattern. cOnclusiOns: 
Patients with risky and acute indications are treated with low waiting times whereas 
patients with less threating skin diseases have to wait longer for appointments at 
dermatological offices.
Objectives: To assess the quality of life (QoL) of patients with an exudative Age-
Related Macular Degeneration (AMD) treated by intravitreal Anti-VEGF (vascular 
endothelial growth factor) and determine its drivers in a real-life setting. MethOds: 
A self-reported survey was carried out among AMD patients belonging to 2 French 
associations. Only patients with exudative AMD and under active intravitreal anti-
VEGF treatment over the last 6 months were included. Data on demographics, 
disease parameters, past and ongoing treatments were collected. One validated 
vision-specific QoL instrument was also considered: the NEI-VFQ-25. Patients were 
stratified into four groups of visual acuity (VA). A multivariate model was performed 
to identify the QoL drivers. Results: Out of the 1,888 questionnaires mailed 32.4% 
were returned and 24.7% fulfilled the inclusions criteria and were fully completed 
for analyses. Patients’ mean age was 78.0 years (SD 7.6). A total of 70.5% were 
women. A total of 60.4% had bilateral disease. The mean duration of symptomatic 
exudative AMD was respectively of 7.2 (SD 5) and 2.3 years (SD 3) for the first and the 
second eye. Most of anti-VEGF treated eyes (n= 641) were treated for more than 1 year 
(77.4%). The mean annual number of anti-VEGF injections was 4.7 (SD 2.7). The mean 
NEI-VFQ-25 global score was 53.4 (SD 21.5). A decrease of this score was positively 
correlated to VA decrease (0.63;p< .0001). This correlation was observed for 11 sub-
scales out of 12. The main risk factor associated to the lower Qol score was the worst 
VA category, with an odds ratio of 5.2 (CI95%[2.6-10.4];p< .0001). cOnclusiOns: In 
a real-life survey of patients treated and followed for exudative AMD, VA decrease 
was the strongest factor linked to QoL worsening. Other factors such as the number 
of Anti-VEGF injections were not correlated to QoL in this study. Then, preservation 
of useful VA still remains a major concern to improve patients’ QoL.
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Objectives: This abstract describes attempts to evaluate the burden of dry eye dis-
ease with regards to vision-related quality of life (QoL) and the causal link to general 
health related quality of life. Recent increased awareness of dry eye disease (DED) 
by both health care professional and patients has been accompanied by improved 
recognition that it is a chronic disorder often requiring long-term treatment and 
management. DED, frequently associated with symptoms of discomfort and visual 
disturbance, also impairs general health status and general quality of life, including 
aspects of physical, social, and psychological functioning. This abstract summarizes 
the available research on the burden of DED and the impact on QoL. MethOds: 
The research included systematic literature search on clinical relevant DED litera-
ture based on HTA relevant requirements, in order to identify potential differences 
within DED. Correlations with socio- demographic characteristics, clinical param-
eters, and psychological status were evaluated. Results: A relative small amount 
of data supporting the effectiveness of DED treatments as assessed by QoL measures 
exists (such as DEQLQ, IDEEL etc.). Dry eye treatments have been associated with 
improvements in symptoms measured by OSDI (Ocular Surface Disease Index), and 
in ophthalmology-disease-specific measurement of QoL, and with enhancement of 
patients’ ratings regarding their ability to perform activities of daily life. Significant 
correlations were found between symptoms score and QoL scores and patient anxi-
ety, especially depression levels which correlates to general health. cOnclusiOns: 
Vision-related QoL in dry eye patients was correlated with general health status, 
especially with anxiety and depression. DED has further implication on general 
public health and deserves an increased attention and resources.
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Objectives: To examine the experience of physicians who treat patients with 
pemphigus vulgaris (PV) in Canada as well as the utilization and access of the drug 
rituximab (Rtx). MethOds: An online questionnaire was created in SurveyMonkey® 
to collect data from participants based on a convenience sample size of 10 English-
speaking dermatologists. Consent was implied once the dermatologist completed the 
questionnaire. Non-identifying information for both dermatologists and PV patients 
was collected. Results: The 10 participating dermatologists have been treating PV 
patients an average of 20.9 ± 10.7 (5 – 45) years in which 28.8 ± 58.3 (0 – 200) was the 
mean number in their practice. Experience with Rtx is based on an average of 4.1 ± 
3.8 (0 – 10) years and 13.1 ± 29.2 (0 – 100) PV patients treated with Rtx. All participants 
answered that “failure of conventional therapy for at least six months” was the pri-
mary reason for using Rtx and that azathioprine, intravenous immunoglobulin and 
mycophenolate mofetil were the most popular treatments used to treat PV patients 
prior to Rtx. On average, it takes 3.2 ± 2.2 (0 – 6) months for a remission to be induced 
after Rtx treatment and 90% of the dermatologists were concerned that infections 
would be an adverse event. Lastly, 6.3 ± 12.3 (0 – 40) was the mean number of Rtx drug 
reimbursement letters that the dermatologists had written on behalf of PV patients 
in which 1.9 ± 2.5 (0 – 6) letters were successful in securing Rtx drug reimburse-
ments. cOnclusiOns: A recent survey of 10 Canadian dermatologists experienced 
with treating PV patients found that Rtx utilization is still new, disease remission is 
achieved within a short period of time, and the drug reimbursement process remains 
a barrier based on the low number of letters written by the dermatologists.
PSS49
real-WorlD utilization Data over 4 yearS of raniBizumaB inJeCtionS 
for the treatment of Wet age-relateD maCular Degeneration in 
CanaDa
Lebel K.1, Gonder J.2, Davies B.1, Zaour N.1
